Business Context and Reporting Period
Company: Repro-Med Systems, Inc. (Note: Input metadata referenced "KORU Medical Systems," but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: February 28, 2009
Business Overview: The Company designs, manufactures, and markets proprietary medical devices for emergency medical applications and ambulatory infusion therapy. Primary products include the FREEDOM60(R) Syringe Infusion System and the RES-Q-VAC(R) Portable Medical Suction System. The Company is classified as a "smaller reporting company."
Key Financial Metrics
| Metric | Fiscal Year 2009 | Fiscal Year 2008 |
|---|---|---|
| Net Sales | $3,439,110 | $2,347,678 |
| Cost of Goods Sold | $1,243,387 | $899,978 |
| Gross Profit Margin | 63.8% | 61.7% |
| Net Operating Profit | $779,011 | $193,509 |
| Net Income (Loss) | $1,030,855 | ($2,499) |
| Net Income Available to Common Shareholders | $1,022,855 | ($10,499) |
| Cash Provided by Operating Activities | $528,180 | $117,614 |
| Working Capital | $1,288,733 | ($50,754) |
| Total Assets | $2,310,409 | $1,304,987 |
| Total Liabilities | $1,605,321 | $1,690,010 |
| Stockholders' Equity | $705,088 | ($385,023) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 46.5% to a record high of $3.44 million, driven primarily by a 74.5% surge in FREEDOM60 sales ($2.27M vs $1.30M) and a 13.8% increase in RES-Q-VAC sales.
- Profitability Turnaround: The Company moved from a net loss of $2,499 in 2008 to a net income of $1.03 million in 2009. This was significantly aided by a $306,000 income tax benefit resulting from the reduction of the valuation allowance on deferred tax assets.
- Expense Management: Stock-based compensation decreased significantly from $160,306 in 2008 to $24,209 in 2009. Interest expense dropped from $200,156 to $51,680 due to loan consolidations and lower rates.
- Liquidity Improvement: Net working capital improved from a deficit of $50,754 to a positive $1.29 million. Cash and cash equivalents rose from $95,561 to $519,209.
- Debt Restructuring: A $400,000 revolving loan from a financial institution was paid off and replaced with a $672,663 term loan from a director at 6% interest over 12 years.
Guidance, Outlook, and Risks
- Outlook: Management expects sales and cash flow to continue increasing, driven by the subcutaneous immune globulin (SCIG) market for the FREEDOM60. The Company believes current capital is sufficient to meet financial needs for the next 12 months.
- Product Development: The Company is developing the "Daisy Set" needle administration system for the FREEDOM60, with FDA 510(k) submission pending. A revised 510(k) for the FREEDOM60 was filed in January 2009.
- Key Risks:
- Reimbursement Dependence: Sales are heavily reliant on Medicare reimbursement codes (specifically E0779 for SCIG). Changes in reimbursement policies could materially affect sales.
- Key Personnel: The Company is dependent on Andrew Sealfon (President/CEO/R&D head). There is no life insurance on his life, and replacement may be difficult.
- Competition: Potential entry of competitors with greater resources or new drug technologies (e.g., Hyaluronidase) could impact market share.
- Regulatory: Products are subject to FDA regulations; failure to comply could result in penalties or recalls.
- Unusual Items: The $306,000 tax benefit was a non-cash adjustment related to the valuation allowance of deferred tax assets, significantly boosting net income.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of the 74.5% growth in FREEDOM60 sales and the stability of the Medicare reimbursement code E0779.
- Related Party Transactions: Review the $672,663 term loan from a director and the $100,000 demand loan from the President, including terms and repayment schedules.
- Key Person Risk: Assess the Company's succession plan given the heavy reliance on President Andrew Sealfon for R&D, sales, and finance.
- Deferred Tax Assets: Confirm the realization of the $306,000 deferred tax asset and the assumptions used for future profitability.
- Product Pipeline: Monitor the FDA approval status of the new "Daisy Set" and the revised FREEDOM60 510(k) filing.